These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 20705397)
1. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Yalcin S Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397 [TBL] [Abstract][Full Text] [Related]
3. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207 [TBL] [Abstract][Full Text] [Related]
4. Current medical treatment of pancreatic neuroendocrine tumors. Yalcin S; Oyan B; Bayraktar Y Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276 [TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics. Ganetsky A; Bhatt V Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450 [TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Oberg K Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940 [TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Pavel ME; Wiedenmann B Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475 [TBL] [Abstract][Full Text] [Related]
8. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy. Chan JA; Kulke MH Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors. Oberg K Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573 [TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors of the pancreas. Milan SA; Yeo CJ Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. Janson ET J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863 [TBL] [Abstract][Full Text] [Related]
12. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Faivre S; Sablin MP; Dreyer C; Raymond E Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547 [TBL] [Abstract][Full Text] [Related]
14. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Raj N; Reidy-Lagunes D Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372 [TBL] [Abstract][Full Text] [Related]
15. State of the art and future prospects in the management of neuroendocrine tumors. Oberg K Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic alternatives in metastatic neuroendocrine tumors. Miller CA; Ellison EC Surg Oncol Clin N Am; 1998 Oct; 7(4):863-79. PubMed ID: 9735138 [TBL] [Abstract][Full Text] [Related]
17. Advances in chemotherapy and biotherapy of endocrine tumors. Oberg K Curr Opin Oncol; 1998 Jan; 10(1):58-65. PubMed ID: 9466486 [TBL] [Abstract][Full Text] [Related]
18. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478 [TBL] [Abstract][Full Text] [Related]